DOCSLIB.ORG

Respiratory Health Spirometry Procedures Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Respiratory Health Spirometry Procedures Manual Respiratory Health Spirometry Procedures Manual January 2008 TABLE OF CONTENTS Chapter Page 1 SPIROMETRY OVERVIEW.......................................................................... 1-1 1.1 Overview of the Spirometry Exam Component.................................. 1-1 1.2 The Bronchodilator Subcomponent .................................................... 1-2 1.3 Chronic Obstructive Pulmonary Disease............................................ 1-3 1.4 Asthma................................................................................................ 1-4 1.5 Basics of Respiration .......................................................................... 1-5 1.6 Spirometric Measurements ................................................................. 1-6 ACKNOWLEDGMENTS AND REFERENCES............................................ 1-13 2 EQUIPMENT AND SUPPLIES...................................................................... 2-1 2.1 List of Equipment and Supplies.......................................................... 2-1 2.2 Description of Equipment and Supplies ............................................. 2-2 2.2.1 Equipment ........................................................................... 2-2 2.2.2 Supplies............................................................................... 2-3 2.3 Equipment Setup Procedures .............................................................. 2-4 2.3.1 Equipment ........................................................................... 2-4 2.3.2 Supplies............................................................................... 2-6 2.4 Equipment Care and Maintenance...................................................... 2-6 2.4.1 Spirometer........................................................................... 2-6 2.4.2 Hoses................................................................................... 2-7 2.5 Equipment Packup Procedures ........................................................... 2-7 2.5.1 Equipment ........................................................................... 2-8 2.5.2 Supplies............................................................................... 2-8 3 EXAMINATION PROTOCOL....................................................................... 3-1 3.1 Eligibility Criteria for Spirometry and Bronchodilator Components ........................................................................................ 3-1 3.2 Spirometry Safety Exclusion Questions ............................................. 3-1 3.3 Spirometry Examination Procedures .................................................. 3-6 3.3.1 Spirometry Testing Procedures ........................................... 3-7 iii TABLE OF CONTENTS (continued) Chapter Page 3.3.2 Instruction and Preparation ................................................. 3-8 3.3.3 Initiate Test......................................................................... 3-10 3.3.4 End of Test .......................................................................... 3-16 3.3.5 Procedures for Repeat Spirometry Testing ......................... 3-18 3.4 Troubleshooting Spirometry Examinations ........................................ 3-20 3.5 Report of Findings .............................................................................. 3-22 4 QUALITY CONTROL.................................................................................... 4-1 4.1 Equipment Cleaning and Calibration.................................................. 4-1 4.1.1 Quality Control Checks Screens ......................................... 4-1 4.1.2 Equipment Cleaning............................................................ 4-5 4.1.3 Equipment Calibration........................................................ 4-5 4.2 Equipment Maintenance..................................................................... 4-8 4.3 Review of Results During the Exam................................................... 4-8 4.4 Observation......................................................................................... 4-9 4.5 Review of Exam Status....................................................................... 4-9 4.6 Review of Results During Analysis.................................................... 4-9 4.7 NIOSH Quality Control Reports......................................................... 4-10 4.7.1 Operator Reports ................................................................. 4-10 4.7.2 Statistics .............................................................................. 4-11 4.7.3 Grades ................................................................................. 4-11 4.7.4 Summary and Trend Analysis Reports................................ 4-11 5 SAFETY PROCEDURES............................................................................... 5-1 5.1 Spirometry Safety Precautions............................................................ 5-1 5.1.1 Safety Exclusion Screening................................................. 5-1 5.1.2 Infection Control Measures................................................. 5-1 5.1.3 Prevention of Electric Shock............................................... 5-2 5.2 Standing vs. Sitting During Spirometric Testing................................ 5-2 5.3 Comprehension or Language Difficulties........................................... 5-3 5.4 Emergency Procedures....................................................................... 5-3 iv TABLE OF CONTENTS (continued) List of Appendixes Appendix Page A NIOSH Spirometry System Design Criteria .................................................... A-1 B Screenshots for Spirometry Safety Exclusion Questions................................. B-1 List of Tables Table 1-1 Lung diseases and spirometry results .............................................................. 1-12 3-1 Spirometry safety exclusion items by age ....................................................... 3-2 List of Figures Figure 1-1 The respiratory tract......................................................................................... 1-5 1-2 Normal volume-time curve.............................................................................. 1-8 1-3 Normal flow-volume curve.............................................................................. 1-8 1-4 FVC and FEV1 on a normal volume-time curve ............................................. 1-9 1-5 FVC on normal flow-volume curve................................................................. 1-9 1-6 Normal and restrictive patterns volume-time curves ....................................... 1-10 1-7 Flow-volume curves........................................................................................ 1-10 1-8 Obstructive pattern shown on a volume-time curve ........................................ 1-11 1-9 Obstructive pattern shown on a flow-volume curve ........................................ 1-11 v TABLE OF CONTENTS (continued) List of Exhibits (continued) Exhibit Page 3-1 Aneurysm help screen...................................................................................... 3-3 3-2 Spirometry exclusion....................................................................................... 3-4 3-3 End of subsection screen.................................................................................. 3-4 3-4 End of exam screen.......................................................................................... 3-5 3-5 Begin spirometry test screen............................................................................ 3-6 3-6 OMI/NIOSH main program screen.................................................................. 3-7 3-7 Proceed with testing screen.............................................................................. 3-8 3-8 Curve display screen – pre-test........................................................................ 3-10 3-9 Curve display screen........................................................................................ 3-11 3-10 Test results screen............................................................................................ 3-12 3-11 Results and quality code box ........................................................................... 3-13 3-12 Override acceptability code screen .................................................................. 3-15 3-13 Post-Test data screen ....................................................................................... 3-16 3-14 End of subsection – complete screen ............................................................... 3-17 3-15 End of exam screen.......................................................................................... 3-18 3-16 Technologist bronchodilator referral script screen .......................................... 3-19 3-17 End of exam – SP to bronchodilator screen..................................................... 3-19 4-1 Quality Control Checks – Start of Stand QC ................................................... 4-2 4-2 Quality Control Checks – Daily QC ................................................................ 4-2 4-3 Quality Control Checks – Start of Session QC................................................ 4-3 4-4 Quality Control Checks – Weekly QC............................................................. 4-3 vi TABLE OF CONTENTS (continued) List of Exhibits (continued) Exhibit Page 4-5 Quality Control Checks – End of Stand QC .................................................... 4-4 4-6 Quality Control Checks
Load more

Recommended publications
  • Effect of an Indwelling Pleural Catheter Vs Talc Pleurodesis On
    This supplement contains the following items: 1. Original protocol, final protocol, summary of changes. 2. Original statistical analysis plan. There were no further changes to the original statistical analysis plan. Downloaded From: https://jamanetwork.com/ on 10/02/2021 The Australasian Malignant Pleural Effusion Trial (AMPLE) A Multicentre Randomized Study Comparing Indwelling Pleural Catheter vs Talc Pleurodesis in Patients with Malignant Pleural Effusions Ethics Registration number 2012-005 Protocol version number 1.0 Protocol date 10/01/2012 Authorised by: Name: Prof YC Gary Lee Role: Chief Investigator Signature: Date: 10/01/2012 Downloaded From: https://jamanetwork.com/ on 10/02/2021 General Information This document describes the Western Australian Randomised Malignant Effusion trial for the purpose of submission for review by the relevant human research and ethics committees. It provides information about procedures for entering patients into the trial and this protocol should not be used as a guide for the treatment of other patients; every care was taken in its drafting, but corrections or amendments may be necessary. Questions or problems relating to this study should be referred to the Chief Investigator or Trial Coordinator. Compliance The trial will be conducted in compliance with this protocol, the National Statement on Ethical Conduct in Human Research, data protection laws and other guidelines as appropriate. It will be registered with the Australia and New Zealand Clinical Trials Registry, once ethical approval is secured.
    [Show full text]
  • Effect of Heliox Breathing on Flow Limitation in Chronic Heart Failure Patients
    Eur Respir J 2009; 33: 1367–1373 DOI: 10.1183/09031936.00117508 CopyrightßERS Journals Ltd 2009 Effect of heliox breathing on flow limitation in chronic heart failure patients M. Pecchiari*, T. Anagnostakos#, E. D’Angelo*, C. Roussos#, S. Nanas# and A. Koutsoukou# ABSTRACT: Patients with chronic heart failure (CHF) exhibit orthopnoea and tidal expiratory flow AFFILIATIONS limitation in the supine position. It is not known whether the flow-limiting segment occurs in the *Istituto di Fisiologia Umana I, Universita` degli Studi di Milano, peripheral or central part of the tracheobronchial tree. The location of the flow-limiting segment Milan, Italy, and can be inferred from the effects of heliox (80% helium/20% oxygen) administration. If maximal #Dept of Critical Care and Pulmonary expiratory flow increases with this low-density mixture, the choke point should be located in the Services, Evangelismos General central airways, where the wave-speed mechanism dominates. If the choke point were located in Hospital, Medical School, University of Athens, Athens, Greece. the peripheral airways, where maximal flow is limited by a viscous mechanism, heliox should have no effect on flow limitation and dynamic hyperinflation. CORRESPONDENCE Tidal expiratory flow limitation, dynamic hyperinflation and breathing pattern were assessed in M. Pecchiari 14 stable CHF patients during air and heliox breathing at rest in the sitting and supine position. Istituto di Fisiologia Umana I via L. Mangiagalli 32 No patient was flow-limited in the sitting position. In the supine posture, eight patients exhibited 20133 Milan tidal expiratory flow limitation on air. Heliox had no effect on flow limitation and dynamic Italy hyperinflation and only minor effects on the breathing pattern.
    [Show full text]
  • Peak Flow Measure: an Index of Respiratory Function?
    International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Peak Flow Measure: An Index of Respiratory Function? D. Devadiga, Aiswarya Liz Varghese, J. Bhat, P. Baliga, J. Pahwa Department of Audiology and Speech Language Pathology, Kasturba Medical College (A Unit of Manipal University), Mangalore -575001 Corresponding Author: Aiswarya Liz Varghese Received: 06/12/2014 Revised: 26/12/2014 Accepted: 05/01/2015 ABSTRACT Aerodynamic analysis is interpreted as a reflection of the valving activity of the larynx. It involves measuring changes in air volume, flow and pressure which indicate respiratory function. These measures help in determining the important aspects of lung function. Peak expiratory flow rate is a widely used respiratory measure and is an effective measure of effort dependent airflow. Aim: The aim of the current study was to study the peak flow as an aerodynamic measure in healthy normal individuals Method: The study group was divided into two groups with n= 60(30 males and 30 females) in the age range of 18-22 years. The peak flow was measured using Aerophone II (Voice Function Analyser). The anthropometric measurements such as height, weight and Body Mass Index was calculated for all the participants. Results: The peak airflow was higher in females as compared to that of males. It was also observed that the peak air flow rate was correlating well with height and weight in males. Conclusions: Speech language pathologist should consider peak expiratory airflow, a short sharp exhalation rate as a part of routine aerodynamic evaluation which is easier as compared to the otherwise commonly used measure, the vital capacity.
    [Show full text]
  • Effects of Calcium on Intestinal Mucin: Implications for Cystic Fibrosis
    27. Takcbayi~shi.S.. (;robe. II . von B;~ssca~t/.D. H.. and rliormnn. 11. Ultrastruc- prepnratlon.) tural a\pects of veihel .llteratlon\ In homoc!\t~nur~a.V~rcha\r'r Arch. Aht. .A 33 Wong. P. W. K.. Scliworl. V . and Komro~er.(i. M.: The b~os!nthc\~\of P;~thol Anat . 1154- 4 (1071). c)st:~thlonrnc In pntlcntc s~thhornoc!\tinur~,~. Ped~at.Rer . 2- 149 (196x1. 28. T:~ndler. H. T.. I:rlandson. R. A,, and Wbnder. E. 1.. Rihol1;lvln and mou\c 34 'The authors would l~kcto thank K. Curleq, N. Becker, and k.Jaros~u\ for thcir hepatic cell structure and funct~on.hmer. J. Pnthol.. 52 69 (1968). techn~cal:Is\l\tancc and Dr\. B. Chomet. Orville T B:llle!. and Mar) B. 29. Ti~nikawa, L.: llltrastructurnl A\pect\ of the I iver and Its I)~sordcr\(Igaker Buschman for the~ruggehtlona In the ~ntcrpretation\of braln and Iner electron Shoin. I.td.. Tok!o. 1968). micrograph\. 30. Uhlendorl, B. W.. Concrl!. E. R.. and Mudd. S. H.: tlomoc!st~nur~a:Studle, In 35 Th~sstud! &a\ \upported b! Publrc Health Servlcc Kese;~rch Grant no. KO1 tissue culture. Pediat. Kes.. 7: 645 (1073). N5OX532NlN and a grant from the Illino~\Department of Mental llealth. 31. Wong. P. W. K.. and Fresco. R.: T~\suec!\tathlon~nc in mice trei~tedw~th 36 Requests for reprint\ should be i~ddressed to: Paul W. K. Wong. M.D.. cystelne and homoser~ne.Pedlat. Res . 6 172 (1972) Department of Ped~atric.Prcsh!tcr~an-St.
    [Show full text]
  • Spirometry Basics
    SPIROMETRY BASICS ROSEMARY STINSON MSN, CRNP THE CHILDREN’S HOSPITAL OF PHILADELPHIA DIVISION OF ALLERGY AND IMMUNOLOGY PORTABLE COMPUTERIZED SPIROMETRY WITH BUILT IN INCENTIVES WHAT IS SPIROMETRY? Use to obtain objective measures of lung function Physiological test that measures how an individual inhales or exhales volume of air Primary signal measured–volume or flow Essentially measures airflow into and out of the lungs Invaluable screening tool for respiratory health compared to BP screening CV health Gold standard for diagnosing and measuring airway obstruction. ATS, 2005 SPIROMETRY AND ASTHMA At initial assessment After treatment initiated and symptoms and PEF have stabilized During periods of progressive or prolonged asthma control At least every 1-2 years: more frequently depending on response to therapy WHY NECESSARY? o To evaluate symptoms, signs or abnormal laboratory tests o To measure the effect of disease on pulmonary function o To screen individuals at risk of having pulmonary disease o To assess pre-operative risk o To assess prognosis o To assess health status before beginning strenuous physical activity programs ATS, 2005 SPIROMETRY VERSUS PEAK FLOW Recommended over peak flow meter measurements in clinician’s office. Variability in predicted PEF reference values. Many different brands PEF meters. Peak Flow is NOT a diagnostic tool. Helpful for monitoring control. EPR 3, 2007 WHY MEASURE? o Some patients are “poor perceivers.” o Perception of obstruction variable and spirometry reveals obstruction more severe. o Family members “underestimate” severity of symptoms. o Objective assessment of degree of airflow obstruction. o Pulmonary function measures don’t always correlate with symptoms. o Comprehensive assessment of asthma.
    [Show full text]
  • In Vitro Modelling of the Mucosa of the Oesophagus and Upper Digestive Tract
    21 Review Article Page 1 of 21 In vitro modelling of the mucosa of the oesophagus and upper digestive tract Kyle Stanforth1, Peter Chater1, Iain Brownlee2, Matthew Wilcox1, Chris Ward1, Jeffrey Pearson1 1NUBI, Newcastle University, Newcastle upon Tyne, UK; 2Applied Sciences (Department), Northumbria University, Newcastle upon Tyne, UK Contributions: (I) Conception and design: All Authors; (II) Administrative support: All Authors; (III) Provision of study materials or patients: All Authors; (IV) Collection and assembly of data: All Authors; (V) Data analysis and interpretation: All Authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Kyle Stanforth. NUBI, Medical School, Framlington Place, Newcastle University, NE2 4HH, Newcastle upon Tyne, UK. Email: [email protected]. Abstract: This review discusses the utility and limitations of model gut systems in accurately modelling the mucosa of the digestive tract from both an anatomical and functional perspective, with a particular focus on the oesophagus and the upper digestive tract, and what this means for effective in vitro modelling of oesophageal pathology. Disorders of the oesophagus include heartburn, dysphagia, eosinophilic oesophagitis, achalasia, oesophageal spasm and gastroesophageal reflux disease. 3D in vitro models of the oesophagus, such as organotypic 3D culture and spheroid culture, have been shown to be effective tools for investigating oesophageal pathology. However, these models are not integrated with modelling of the upper digestive tract—presenting an opportunity for future development. Reflux of upper gastrointestinal contents is a major contributor to oesophageal pathologies like gastroesophageal reflux disease and Barratt’s oesophagus, and in vitro models are essential for understanding their mechanisms and developing solutions.
    [Show full text]
  • BSL Lesson 13
    Physiology Lessons Lesson 13 for use with the PULMONARY FUNCTION II Biopac Student Lab Pulmonary Flow Rates Forced Expiratory Volume (FEV1,2,3) PC under Windows 95/98/NT 4.0/2000 Maximal Voluntary Ventilation (MVV) or Macintosh Manual Revision 12132000.PL3.6.6-ML3.0.7 Number of cycles in 12 second interval Average Volume Richard Pflanzer, Ph.D. per cycle Associate Professor Indiana University School of Medicine Purdue University School of Science J.C. Uyehara, Ph.D. Biologist Number of cycles/minute = Number of cycles in 12 second interval X 5 MVV = (Average volume per cycle) X (Number of cycles per minute) BIOPAC Systems, Inc. William McMullen Vice President BIOPAC Systems, Inc. BIOPAC Systems, Inc. 42 Aero Camino, Santa Barbara, CA 93117 (805) 685-0066, Fax (805) 685-0067 Email: [email protected] Web Site: http://www.biopac.com Page 2 Lesson 13: Pulmonary Function II Biopac Student Lab V3.0 I. INTRODUCTION The respiratory or pulmonary system performs the important functions of supplying oxygen (O2) during inhalation, removing carbon dioxide (CO2) during exhalation, and adjusting the acid-base balance (pH) of the body by removing acid-forming CO2. Because oxygen is necessary for cellular metabolism, the amount of air that the pulmonary system provides is important in setting the upper limits on work capacities or metabolism. Therefore, the measurement of lung volumes and the rate of air movement (airflow) are important tools in assessing the health and capacities of a person. In this lesson, you will measure: Forced Vital Capacity (FVC), which is the maximal amount of air that a person can forcibly exhale after a maximal inhalation.
    [Show full text]
  • Restrictive Lung Disease
    Downloaded from https://academic.oup.com/ptj/article/48/5/455/4638136 by guest on 29 September 2021 RESTRICTIVE LUNG DISEASE WARREN M. GOLD, M.D. RESTRICTIVE LUNG DISEASE is a These disorders can be divided into two pattern of abnormal lung function defined by groups: extrapulmonary and pulmonary. a decrease in lung volume (Fig. I).1,2 The In extrapulmonary restriction, an abnormal total lung capacity is decreased and, in severe increase in the stiffness of the chest wall (kypho­ restrictive defects, all of the subdivisions of the scoliosis) restricts the lung volumes, as does total lung capacity including vital capacity, respiratory muscle weakness (poliomyelitis or functional residual capacity, and residual vol­ muscular dystrophy). These extrapulmonary ume are decreased. In mild or moderately se­ causes of pulmonary restriction are treated vere restrictive defects, the residual volume may be normal or slightly increased. CLINICAL DISORDERS CAUSING TABLE 1 RESTRICTIVE LUNG DISEASE CAUSES OF RESTRICTIVE LUNG DISEASE Restrictive lung disease is not a specific clin­ I. Extrapulmonary restriction 3 ical entity, but only one of several patterns of A. Chest wall stiffness (kyphoscoliosis) B. Respiratory-muscle weakness (muscular dystrophy)4 abnormal lung function. It is produced by a C. Pleural disease (pneumothorax)5 number of clinical disorders (see Table 1). II. Pulmonary restriction A. Surgical resection (pneumonectomy)6.7 Dr. Gold: Director, Pulmonary Laboratory and Re­ B. Tumor (bronchogenic carcinoma or metastatic tumor)8 search Associate in Cardiology (Pulmonary Physiology), C. Heart disease (hypertensive, arteriosclerotic, rheu­ Children's Hospital Medical Center; Associate in Pedi­ matic, congenital)9 atrics and Tutor in Medical Science, Harvard Medical 10 11 School, Boston, Massachusetts.
    [Show full text]
  • Methacholine Challenge Test 1 2
    Methacholine Challenge Test 1 2 What is Methacholine Challenge Test (MCT)? Also, • Do not consume a heavy meal within 2 hours of the test. You can have a light It is a test that measures if your airways narrow after inhaling specific provoking meal e.g. sandwich, soup or salad within 2 hours before the test. agent. The provoking agent used in this test is inhaled methacholine. The degree • Do not wear any tight clothes. of resultant airway narrowing is dependent on each individual’s susceptibility and this airway narrowing will be assessed objectively by measuring the lung function You may also need to stop certain medications before taking the test depending on what clinical questions your physician would like answered based on your MCT changes before and after inhalation of the methacholine in progressively larger results. Different medications have to be stopped at different times before the test doses. Increased airway hyperresponsiveness is usually a hallmark feature of asthma. depending on how long they stay in your body. It is important for you to check with your doctor regarding the safety of stopping Why do I need this operation/procedure? these medications before discontinuing them for the test. Commonly, if you had presented with respiratory symptoms such as shortness of How long before the test? Avoid the following: breath, wheezing, chest tightness or cough, 6weeks Omalizumab your physician may consider doing a MCT to 1week Tiotropium (Spiriva) establish the diagnosis of asthma, especially if 48hours Combination inhalers such as Seretide (fluticasone/ initial lung function tests have not confirmed salmeterol) or Symbicort (budesonide/formoterol) or the diagnosis.
    [Show full text]
  • Standardisation of Spirometry
    Eur Respir J 2005; 26: 319–338 DOI: 10.1183/09031936.05.00034805 CopyrightßERS Journals Ltd 2005 SERIES ‘‘ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING’’ Edited by V. Brusasco, R. Crapo and G. Viegi Number 2 in this Series Standardisation of spirometry M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P.M. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi and J. Wanger CONTENTS AFFILIATIONS Background ............................................................... 320 For affiliations, please see Acknowledgements section FEV1 and FVC manoeuvre .................................................... 321 Definitions . 321 CORRESPONDENCE Equipment . 321 V. Brusasco Requirements . 321 Internal Medicine University of Genoa Display . 321 V.le Benedetto XV, 6 Validation . 322 I-16132 Genova Quality control . 322 Italy Quality control for volume-measuring devices . 322 Fax: 39 103537690 E-mail: [email protected] Quality control for flow-measuring devices . 323 Test procedure . 323 Received: Within-manoeuvre evaluation . 324 March 23 2005 Start of test criteria. 324 Accepted after revision: April 05 2005 End of test criteria . 324 Additional criteria . 324 Summary of acceptable blow criteria . 325 Between-manoeuvre evaluation . 325 Manoeuvre repeatability . 325 Maximum number of manoeuvres . 326 Test result selection . 326 Other derived indices . 326 FEVt .................................................................. 326 Standardisation of FEV1 for expired volume, FEV1/FVC and FEV1/VC.................... 326 FEF25–75% .............................................................. 326 PEF.................................................................. 326 Maximal expiratory flow–volume loops . 326 Definitions. 326 Equipment . 327 Test procedure . 327 Within- and between-manoeuvre evaluation . 327 Flow–volume loop examples. 327 Reversibility testing . 327 Method .
    [Show full text]
  • Expiratory Capnography in Asthma
    Eur Respir J, 1994, 7, 318–323 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07020318 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Expiratory capnography in asthma: B. You*, R. Peslin**, C. Duvivier**, V. Dang Vu*, J.P. Grilliat* Expiratory capnography in asthma: evaluation of various shape indices. B. You, R. *U.M.G., Service de Médecine H, Hôpital Peslin, C. Duvivier, V. Dang Vu, J.P. Grilliat. ERS Journals Ltd 1994. Central, Nancy, France. **INSERM, Unité ABSTRACT: The shape of the capnogram is modified by airway obstruction, and 14, Physiopathologie Respiratoire, Vandœuvre- the evaluation of this deformation, using measurable indices, could allow an indi- les- Nancy, France. rect measurement of bronchial patency. A previous study undertaken in asthmat- Correspondence: B. You ic subjects showed a good correlation between a capnographic index (end-tidal slope) 19 Avenue du Vieux Château and a spirometric parameter (forced expiratory volume in one second as a per- Vandœuvre-les-Nancy centage of predicted (FEV1 %pred)) and suggested the study of other indices. 54500 The correlations between capnographic and spirometric indices were measured France in 10 healthy subjects and 30 asthmatic patients. The usefulness of eight descriptive indices, analysing the successive phases of the capnogram, was assessed by measur- Keywords: Asthma ing their reproducibility and their sensitivity to airway obstruction. The intra- capnography individual and interindividual variabilities (Vi and VI) and the noise/signal ratio carbon dioxide lung function tests (Vi/VI) were measured by comparing the results of two successive capnographic monitoring measurements in 14 asthmatic subjects.
    [Show full text]
  • Spirometry (Adult) Guideline
    Document Number # QH-GDL-386:2012 Spirometry (Adult) Respiratory Science Custodian/Review Officer: 1. Purpose Chief Allied Health Officer This guideline provides recommendations regarding best practice to support high quality spirometry practice Version no: 1.0 throughout Queensland Health facilities. Applicable To: 2. Scope All Health Practitioners performing adult This guideline provides information for all health spirometry practitioners who perform adult spirometry as part of their clinical duties. Approval Date: 26/11/2012 This guideline provides the minimum requirements for obtaining acceptable and repeatable pre- and post- Effective Date: 26/11/2012 bronchodilator (reversibility) spirometric data using both volume and flow-measuring devices. Next Review Date: 26/11/2013 3. Related documents Authority: This guideline is primarily based on the following Chair – State-wide Clinical Measurements Network documents taken from the series “ATS/ERS Task Force: Standardisation of Lung Function Testing” Approving Officer General considerations for lung function testing 1 Chief Allied Health Officer (2005). Standardisation of spirometry (2005). 2 References from alternate sources of information have Supersedes: Nil been identified in this document. Key Words: spirometry, spiro, respiratory, Policy and Standard/s: measure, spirogram, spirometric, bronchodilator, flow-volume loop, peak Informed Decision-making in Healthcare (QH-POL- flow 346:2011) 3 Accreditation References: Procedures, Guidelines, Protocols EQuIP and other criteria and standards Australian Guidelines for the prevention and control of infection in healthcare (CD33:2010) 4 2005 American Thoracic Society and European Respiratory Society (ATS/ERS) guidelines 1, 2 Version No.: 1.0; Effective From: 26 November 2012 Page 1 of 31 Printed copies are uncontrolled Queensland Health: Spriometry (Adult) Queensland Health Paediatric Spirometry Guideline Forms and templates Nil 4.
    [Show full text]